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Purpose: To assess the impact of increasing dose on overall survival (OS) for prostate cancer patients.
Methods: Treatment data were obtained on more than 20,000 patients in the National Oncology Data Alliance®, a
proprietary database of merged tumor registries, who were treated for prostate cancer with definitive radiotherapy
between 1995 and 2006. Eligible patients had complete data on total dose, T stage, use and timing of androgen
deprivation therapy (ADT), and treatment start date (n = 20,028). Patients with prior malignancies were excluded.
Results: On multivariate analysis, dose, T stage, grade, marital status, age, and neoadjuvant ADT were significant
predictors of OS. Hazard ratios for OS declined monotonically with increasing dose, reaching 0.63 (95 % Confidence
Interval 0.53–0.76) at ≥80 Gy. On subset analysis, neoadjuvant ADT significantly improved OS in high risk patients
but was not significant in lower risk patients. The dose response was maintained across all risk groups. Medical
comorbidities were balanced across all dose strata and sensitivity analysis demonstrated that other prognostic
factors were unlikely to explain the observed dose response.
Conclusions: This study suggests that increasing dose significantly improves OS in prostate cancer patients treated
with radiotherapy.
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Dose-escalated radiotherapy provides superior freedom
from clinical and biochemical failure in men treated for
prostate cancer (PCa) [1–5] and is widely used in clinical
practice [6]. Combined androgen deprivation therapy
(ADT) and radiotherapy have demonstrated an OS ad-
vantage in intermediate and high risk patients in mul-
tiple randomized clinical trials (RCTs), albeit at doses
≤70 Gy [7–10]. Retrospective series have suggested that
the benefit of dose escalation may be greater than that
of ADT with conventional doses [11]. With a median
follow-up of 7 years, Radiation Therapy Oncology Group
(RTOG) 0126 showed significant improvements in the
rates of biochemical failure and distant metastases with
dose-escalated radiotherapy, but no OS benefit has been
observed with higher doses to date [12].
The optimal radiotherapy dose must balance the risks
and benefits of improved local control relative to* Correspondence: mhall@coh.org
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unless otherwise stated.treatment morbidity, but a treatment benefit in terms of
improved OS is generally assumed [13, 14]. Given the
potential toxicities of therapy and growing evidence that
the treatment benefit in men with indolent PCa is lim-
ited [15, 16], it is important to analyze the outcomes of
dose-escalated therapy in a population-based cohort to
characterize this benefit where randomized data with ad-
equate statistical power have been lacking. Therefore,
the purpose of this study is to assess the impact on OS
of increasing dose in PCa patients treated with definitive
radiotherapy using a large database and to quantify the
effects of prognostic factors.Methods
Patient selection
Data on all men diagnosed with PCa from 1995 through
2006 were extracted from the National Oncology Data
Alliance® (Elekta/IMPAC Medical Systems, Inc., Sunnyvale,
CA and Stockholm, Sweden), a proprietary database of
merged tumor registries. The registry is fully compliant
with American College of Surgeons (ACOS) regulatoryis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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more than 150 hospitals in the United States. Data in the
NODA registries are exactly the data sent to state tumor
registries and to Surveillance, Epidemiology, and End Re-
sults (SEER), in regions that participate in SEER [17].
The study population included all patients treated with
definitive radiotherapy with complete data on total dose,
T stage, use and timing of ADT, and treatment start
dates. Patients who underwent prostatectomy or brachy-
therapy, had distant disease, or had history of prior ma-
lignancy were excluded, leaving 20,028 evaluable
patients. Patient characteristics included age, race, mari-
tal status, T stage, grade, total dose, ADT use, year of
diagnosis, year of treatment, and medical comorbidities.
In ACOS registries, Gleason scores are binned into four
histologic grades [18]. PSA values were not available.
This study was conducted with the approval of the City
of Hope Institutional Review Board.
The primary endpoint was OS, measured from the
start of treatment to the date of death from any cause.
Participating institutions regularly update patient files
with vital status. For patients reported alive at last
follow-up, the Social Security death index (SSDI) was
searched to extend follow-up duration. OS outcomes
were updated through November 1, 2011, the last date
that state death records were included in the Death
Master File by the Social Security Administration as per
Section 205r of the Social Security Act. Patients alive as
of this date were censored.
Statistical analysis
Statistical analysis was performed using SPSS v. 18.0 (SPSS
Inc., Chicago) after patient-identifiers were removed from
the data set. Multivariate proportional hazards analysis
(MVA) was used to identify factors associated with OS [19].
The proportional hazards assumption was tested for a non-
zero slope in the generalized linear model using scaled
Schoenfeld residuals, and no substantial deviations were de-
tected. Survival curves were plotted by Kaplan-Meier and
compared using the log-rank test. For survival analysis,
dose was considered as a categorical variable with three
dose bins (68–71.99 Gy, 72–75.99 Gy, and ≥76 Gy). For
MVA, the effect of dose was also analyzed as a categorical
variable and was divided into seven dose bins with 68–
69.99 Gy as the referent category. Correlation between sig-
nificant prognostic variables and dose was examined by
least squares regression and by plotting studentized resid-
uals. MVA was performed with variates common to both
the NODA and the Surveillance, Epidemiology, and End
Results (SEER) database to confirm the validity of the data
and the findings [17]. MVA yielded similar hazard ratios
(HRs) and demonstrated congruence between the two data-
bases (Additional file 1: Appendix 1). To address the poten-
tial differences between this retrospective study and RCTs,5-year OS was calculated for our data and RCTs using high
risk patients in both cases.
Sensitivity analysis
The observed differences in OS between groups receiv-
ing different radiotherapy doses may reflect the effects
of an unmeasured variable, like PSA, leading to a false
association between dose and OS. For example, assign-
ing patients to lower doses because they have higher
PSAs and reduced life expectancy could mimic a dose
response. Sensitivity analysis was performed to measure
the potential influence of an unmeasured confounder on
the hazard ratio (HR) estimate for OS. The association
between dose and OS may be affected by the prevalences
of the unmeasured confounder in the dose groups and
its HR (HRconfounder), which was assumed to be inde-
pendent of dose. Only sampling bias for an unmeasured
confounder with HR > 1 and higher prevalence in the
lower dose group can mimic the dose response [20, 21].
Sensitivity analysis estimated the necessary prevalence to
mimic the perceived dose response based on the pres-
ence of the confounder. Williams et al. showed that pa-
tients had significantly worse OS with pretreatment 40 ≥
PSA > 20 (HR = 1.32) and PSA > 40 (HR = 1.91), com-
pared to patients with PSA < 10. [22]. Therefore, we
modeled the effect of the putative confounder as a PSA
imbalance using these published values.
Following the work of Lin et al., the degree of imbal-
ance needed between dose groups to mimic the ob-
served dose response is given by,







where Plow and Phigh are the prevalences of the con-
founder in the low and high dose groups, respectively,
and HRdose is the observed HR for dose from the MVA
(See Additional file 1: Appendix 2).
Results
Patients
Patient demographics and tumor characteristics are pre-
sented in Table 1. Median age was 71 years. ADT was
administered in 40 % of patients as neoadjuvant or con-
current therapy with radiotherapy, defined as beginning
within 6 months of the radiotherapy start date. The first
notation for the use of intensity-modulated radiotherapy
(IMRT) occurred in 2002. The prevalence of significant
comorbidities was similar across all dose groups.
Outcomes
Median follow-up was 8.6 years for surviving patients.
At the close-out date, 40 % of patients had died. The
Kaplan-Meier curves showed a clear and statistically
Table 1 Patient demographics
Dose 68–69.99 Gy 70–71.99 Gy 72–73.99 Gy 74–75.99 Gy 76–77.99 Gy 78–79.99 Gy ≥80 Gy
Number of patients 4,565 3,956 4,594 3,604 2,007 628 674
Age (Years) Median 72 71 71 70 71 71 71
Interquartile Range [67, 76] [66, 75] [66, 75] [65, 75] [65, 75] [66, 76] [66, 75]
Race White 85 % 81 % 84 % 82 % 85 % 82 % 86 %
Black 12 % 16 % 14 % 15 % 12 % 16 % 12 %
Asian/American Indian 1 % 1 % 1 % 1 % 1 % 1 % 1 %
Unknown 2 % 2 % 1 % 2 % 2 % 1 % 1 %
Marital status Single 18 % 17 % 20 % 20 % 22 % 21 % 23 %
Married 74 % 74 % 72 % 67 % 69 % 68 % 72 %
Unknown 8 % 9 % 8 % 13 % 9 % 11 % 5 %
T stage T1 44 % 45 % 57 % 57 % 59 % 53 % 52 %
T2 47 % 45 % 37 % 37 % 36 % 37 % 34 %
T3 8 % 9 % 5 % 5 % 4 % 9 % 13 %
T4 1 % 1 % 1 % 1 % 1 % 1 % 1 %
Grade (1) Well Differentiated 11 % 8 % 3 % 2 % 2 % 1 % 1 %
(2) Moderately Differentiated 57 % 58 % 59 % 55 % 45 % 41 % 42 %
(3) Poorly Differentiated 19 % 23 % 33 % 40 % 51 % 54 % 55 %
(4) Anaplastic <1 % <1 % <1 % <1 % <1 % 1 % 1 %
Unknown 13 % 11 % 5 % 3 % 2 % 3 % 1 %
High risk T3-T4 or Grade 3–4 23 % 29 % 35 % 42 % 53 % 59 % 60 %
Androgen deprivation No 68 % 59 % 53 % 54 % 54 % 50 % 59 %
Therapy Yes 32 % 41 % 47 % 46 % 46 % 50 % 41 %
Year treated 1995–1997 54 % 31 % 5 % 1 % 1 % 1 % <1 %
1998–2000 32 % 40 % 15 % 5 % 3 % 3 % <1 %
2001–2003 11 % 19 % 37 % 30 % 20 % 14 % 16 %
2004–2006 3 % 10 % 43 % 64 % 76 % 82 % 83 %
Medical Cardiovascular Disease 13 % 19 % 16 % 15 % 21 % 25 % 18 %
Comorbidities Diabetes mellitus 5 % 9 % 4 % 5 % 8 % 7 % 7 %
Respiratory Disease 2 % 3 % 2 % 2 % 3 % 5 % 2 %
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(Fig. 1). Median OS was 11.4 years (95 % Confidence
Interval [CI] 11.1–11.6) for 68–71.99 Gy, 12.0 years
(95 % CI 11.6–12.3) for 72–75.99 Gy, and 12.8 years
(95 % CI 10.9–14.7) for ≥76 Gy.
Dose, T stage, grade, age, marital status, and neoadjuvant
ADT were significant on MVA (Table 2). Race and
treatment year were not significant. When dose was de-
fined as a categorical variable with seven dose bins
using 68–69.99 Gy as the referent category, the same
variables were significant and no additional factors were
significant. Adjusting for the effect of other prognostic fac-
tors, HRs for OS declined monotonically with increasing
dose, reaching 0.63 (95 % CI 0.53–0.76) at ≥80 Gy, without
evidence of a plateau (Fig. 2). Even using the 74–76 Gy
group (HR = 0.83, 95 % CI 0.77–0.90) as the referentcategory, treatment with ≥80 Gy maintained its significant
OS advantage.
On MVA, patients treated with higher doses also experi-
enced a significant improvement in cause-specific survival
(CSS). Using 68–71.99 Gy as the referent category, the HRs
for CSS decreased sequentially to 0.62 (95 % CI 0.49–0.78)
for 72–75.99 Gy and 0.26 (95 % CI 0.12–0.55) for ≥76 Gy.
As an exploratory analysis, patients were organized
into high and low risk groups, approximating the Na-
tional Comprehensive Cancer Network risk categories.
Patients with either T3-T4 stage or Grade 3–4 histology
were classified as high risk. In our analysis, T1 and T2,
Grade 1 and T1, Grade 2 patients had comparable HRs
for OS and were classified as low risk and T2 Grade 2
patients were categorized as intermediate. Dose retained
significance on MVA for low, intermediate, and high risk


























≥ 76 Gy 3,309 3,257 3,100 2,485 995 152
72-75.99 Gy 8,198 7,957 7,483 6,346 3,689 1,262




Fig. 1 Overall survival (OS) by dose group. The Kaplan-Meier curves showed a clear and statistically significant association between higher radiotherapy
dose and improved OS (p < 0.0001)
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three subgroups. On subset analysis, ADT provided a
significant OS benefit in high risk patients (HR 0.87,
95 % CI 0.81–0.94), but was not significant in lower risk
patients on MVA (p > 0.5).
Dose was not correlated with age, race, marital status,
T stage, grade, and neoadjuvant ADT. IMRT was first
noted in patient records in 2002. When all patients
treated in 2002 or later were excluded, dose remained
statistically significant on MVA with small changes in
the observed HRs. In the multivariate setting, there was
no suggestion or trend of improved OS in later years
(p > 0.7). Thus, the dose response does not appear to be
an effect of treatment technique.
Treatment outcomes were examined with patients di-
vided into three age subgroups (< 65, 65–74, and
≥75 years) to determine if the benefit associated with
high dose treatment was greater in younger patients.
HRs for OS were comparable in patients of all ages,
adjusting for the effects of increasing age on mortality.
The association between dose and improved OS was
evident in all subgroups examined, including stratifica-
tion by ADT use. The observed OS advantage remained
significant when patients who died within 6 months, 1,
2, 3, and 5 years of treatment were excluded, indicating
that the benefit of high dose treatment was not related
to an imbalance in the number of patients with abbrevi-
ated life expectancy consigned to receive lower doses.Reported medical comorbidities were balanced across all
dose strata.
Five-year OS estimates for our study and for RCTs en-
rolling high risk patients treated with external beam
radiotherapy and ADT are shown in Fig. 3 [10, 23–26].
All patients in our study had a minimum 5-year follow-
up, making 5-year OS a fair metric for comparison. Five-
year OS was similar for RCTs and our cohort, suggesting
not only that a very similar dose response was operative
in both this study and the RCTs, but that the demo-
graphics and survival from non-PCa-related deaths were
similar for all of these patient populations.
Sensitivity analysis was performed to assess the poten-
tial effects of an unmeasured confounder on the esti-
mated HR for dose. The observed dose response could
be simulated mathematically if patients in the high dose
groups had lower pretreatment PSAs than patients in
the lower dose groups. To determine the degree of PSA
disparity needed to achieve the observed HR for OS, we
assumed that all patients in the ≥80 Gy group had PSA
< 10. We then calculated the prevalence of patients with
elevated pretreatment PSA in the 68–70 Gy group that
must be present to match the observed HRdose = 0.63
(Table 2). To replicate the dose response, the 68–70 Gy
group must have either 65 % of patients with PSA > 40
(HR = 1.91) and the remainder with PSA < 10 or 45 %
with PSA > 40 and the remainder with 40 ≥ PSA > 20
(HR = 1.32) [22]. Thus, the median PSA must be
Table 2 Hazard ratios for overall survival
p-value HR 95 % CI
Dose (Gy) 68–69.99 <0.001 ≡1.00
70–71.99 0.206 0.96 [0.91, 1.02]
72–73.99 <0.001 0.86 [0.81, 0.92]
74–75.99 <0.001 0.83 [0.77, 0.90]
76–77.99 <0.001 0.76 [0.68, 0.84]
78–79.99 <0.001 0.71 [0.59, 0.84]




Therapy Yes 0.009 0.94 [0.90, 0.98]
T stage T1 <0.001 –
T2 <0.001 1.19 [1.14, 1.25]
T3 <0.001 1.40 [1.29, 1.53]
T4 <0.001 2.38 [1.90, 2.97]
Grade (1) Well Differentiated <0.001 –
(2) Moderately
Differentiated
0.058 1.09 [1.00, 1.20]
(3) Poorly
Differentiated
<0.001 1.41 [1.28, 1.56]
(4) Anaplastic 0.001 1.78 [1.25, 2.52]
Age (Continuous) <0.001 1.04 [1.04,1.05]
Marital status Unmarried –
Married <0.001 0.80 [0.76, 0.85]
HR Hazard ratio, CI Confidence interval
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the observed OS difference.
A disparity in the prevalence of a medical comorbidity,
such as cardiovascular disease, could also have this ef-
fect, but the recorded prevalence of significant comor-
bidities was similar across all dose groups.Fig. 2 Hazard ratios for overall survival by dose group on multivariate
analysis. Adjusting for the effect of other factors, hazard ratios for overall
survival declined monotonically with increasing dose. Diamonds
correspond to the observed hazard ratio for each dose group. The
error bars indicate the standard error of the hazard ratioDiscussion
This observational study is the largest on PCa treated
with known radiotherapy doses. On MVA, dose was a
clear and statistically significant prognostic factor for OS
without evidence of plateau up to 82 Gy. On subset ana-
lysis, ADT was protective in high risk patients but was
not significant in low risk patients, whereas dose was
significant in both low and high risk patients. The asso-
ciation between dose and improved OS was evident in
all subgroups examined, including stratification by age
and treatment with and without ADT. Although a retro-
spective analysis cannot account for all patient factors,
the dose response was durable across a number of clin-
ical scenarios and this analysis accounted for potential
disparities in medical comorbidities. Sensitivity analysis
also suggested that the presence of other uncoded vari-
ables, such as PSA, was unlikely to explain the observed
dose response.
Several limitations in our study should be acknowl-
edged. Although this study is the largest to address the
impact of increasing dose on OS in patients with local-
ized PCa treated with definitive radiotherapy, the data
do not enable the opportunity to examine several im-
portant factors, including duration of ADT, use of pelvic
nodal radiotherapy, and complications. Second, outcome
measures were limited to OS and CSS, and data regard-
ing local and distant failure cannot be extracted. Third,
patient selection can influence the results in population-
based observational series and must be considered when
applying our results to clinical practice.
The completeness of the available data, however, helps
to counter the possibility that the observed benefit of
high dose radiotherapy is due solely to selection bias.
First, the advantage of high dose remained when patients
with shortened life expectancy (dying within 6 months
to 5 years after treatment) were excluded. Second, the
HRs for dose were consistent across all age groups, indi-
cating that the benefit of high dose therapy was not
biased by age discrepancies. Third, sensitivity analysis
demonstrated that the observed dose response could be
mimicked only by an unrealistic disparity in the preva-
lence of an unmeasured variable such as PSA that se-
verely compromised survival. The agreement of this
study with RCTs (Fig. 3) strongly imply that patients in
this retrospective study were no more likely, at any dose,
to have life-threatening comorbidities than patients in
RCTs. Consequently, the accuracy of HR estimates may
be affected by unmeasured variables, but reason dictates
that these findings represent a true biological dose
response.
RCTs provide precise measures and comparisons of
treatment efficacy, have excellent internal validity, and
are less prone to bias. Population-based observational
studies cannot replace randomized data as the standard
Fig. 3 Five-year overall survival for randomized clinical trials in men with high risk prostate cancer treated with radiotherapy and androgen deprivation
therapy. Also shown are data for high risk patients treated with androgen deprivation therapy in this study
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of the effectiveness of therapies in the general popula-
tion and it can address questions that have not been
adequately evaluated in RCTs [27]. The impact of bias
can be minimized in observational studies by account-
ing for important covariates, including comorbidity,
that are controlled in RCTs. In addition, the impact of
unmeasured variables, such as PSA, can also be esti-
mated using sensitivity analysis (as we did here). With
careful planning, population-based observational stud-
ies can help to answer important clinical questions and
fill the knowledge gaps left by existing randomized
data.
Of note, PSA cannot be reliably extracted from US
population-based databases before 2004, and changes
in Gleason score measurements over time could result
in upgrading of tumors diagnosed in later years [28].
Finally, increasing dose conferred a clear and statisti-
cally significant OS benefit, but the magnitude of bene-
fit was modest. In this study, the median survival for
patients treated with ≥76 Gy was 12.8 years compared
to 11.4 years for 68–72 Gy. Men diagnosed with PCa
have competing causes of mortality, including cardio-
vascular disease and second cancers [29, 30]. Appropriate
patient selection is clearly an important consideration
in the decision to treat that is beyond the scope of this
study. Once this decision is made, however, our study
suggests that treatment with higher dose and ADT in
high risk patients confers a significant OS benefit. Only
a prospective RCT can provide absolute measures of
this advantage.Five randomized dose escalation trials have shown super-
ior freedom from failure at higher doses, but were under-
powered to detect an OS difference [1–5]. In 393 patients
receiving radiotherapy followed by proton boost to 70.2 vs.
79.2 GyE, Zietman et al. reported 5-year OS rates of 96 %
and 97 %, respectively. Given the 96 % OS for the low dose
group, no survival advantage could have been demon-
strated in this study [1]. Kuban et al. reported no difference
in 8-year OS in 303 patients treated with either 70 or
78 Gy. However, 73 % of patients were censored, salvage
ADT was used in an unknown number of cases, and only
10 patients died of PCa [4]. In the largest dose escalation
trial, Dearnaley et al. reported 10-year OS of 71 % in 843
patients treated with either 64 or 74 Gy. All patients re-
ceived neoadjuvant and concurrent ADT, regardless of risk
status [2].
RTOG 0126 demonstrated a significant reduction in bio-
chemical failure and distant metastases with higher doses,
but not an improvement in OS after a median follow-up of
7 years. Given the small number of CSS events to date,
however, this finding is not unexpected and longer follow-
up is required to credibly address this question, even in an
adequately powered clinical trial [12].
In our study, increasing dose was associated with a sig-
nificant OS benefit. The small incremental benefit of
1.4 years median survival, however, required thousands
of patients to detect this difference at a level of statistical
significance. A dose response can only be conclusively
demonstrated in a clinical trial. To answer this question,
two RCTs in the United States that were powered to de-
tect an OS difference are maturing and ongoing. Our
Hall et al. Radiation Oncology  (2015) 10:115 Page 7 of 8findings, however, suggest that although a dose response
for OS exists, the magnitude of this advantage may com-
promise their ability to verify this outcome.
Conclusions
In a large population-based cohort, our study suggests
that OS is significantly improved in PCa patients in all
risk groups treated with higher doses. The analysis also
indicates that medical comorbidities, PSA, and other
prognostic factors cannot credibly account for the ob-
served dose response. We conclude that treatment with
higher dose should be considered in all PCa patients re-
ceiving definitive radiotherapy provided that acceptable
toxicity constraints can be achieved.
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